Shares of Tracon Pharmaceuticals Inc. (NASDAQ:TCON) traded up 10% on Wednesday . The stock traded as high as $4.90 and last traded at $4.61, with a volume of 76,476 shares trading hands. The stock had previously closed at $4.19.

Separately, Zacks Investment Research downgraded Tracon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 20th.

The firm’s market cap is $61.02 million. The stock’s 50-day moving average is $5.88 and its 200-day moving average is $7.01.

Tracon Pharmaceuticals (NASDAQ:TCON) last released its earnings results on Wednesday, May 11th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.16. Equities analysts anticipate that Tracon Pharmaceuticals Inc. will post ($2.55) EPS for the current fiscal year.

TRACON Pharmaceuticals, Inc (TRACON) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, age-related macular degeneration (AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).